Monopar Therapeutics Research And Development Expense

• Monopar Therapeutics showed a decrease of -23.8% in Research And Development Expense from 2024 to 2025.
• This data is from Monopar Therapeutics's annual report (Form 10-K), filed with the SEC on March 27, 2026.
• XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 10 years of available data (2016 to 2025), Monopar Therapeutics's Research And Development Expense has grown by 3,432.7%.
• Historical annual values: Fiscal year 2025: $9.90 million | Fiscal year 2024: $13.01 million | Fiscal year 2023: $5.60 million | Fiscal year 2022: $7.59 million | Fiscal year 2021: $6.49 million | Fiscal year 2020: $4.07 million | Fiscal year 2019: $1.97 million | Fiscal year 2018: $1.77 million | Fiscal year 2017: $935.3 thousand | Fiscal year 2016: $280.4 thousand.
• Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: June 20, 2026